PLA2G5 as a Radioligand Therapy Target
PLA2G5, phospholipase A2 group V, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, PLA2G5 staining is highest in kidney cancer (90% of samples positive), liver cancer (92% of samples positive) and thyroid cancer (75% of samples positive). Clinical status: Clinical-stage (up to phase 3, any modality).
Is PLA2G5 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in kidney cancer, 90% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: Clinical-stage (up to phase 3, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
PLA2G5 expression in cancer
Protein expression of PLA2G5 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Kidney Cancer | 0.70 | High | 90% |
| Liver Cancer | 0.58 | High | 92% |
| Thyroid Cancer | 0.50 | Medium | 75% |
| Melanoma | 0.48 | Medium | 82% |
| Pancreatic Cancer | 0.47 | Medium | 83% |
| Prostate Cancer | 0.47 | Medium | 75% |
| Endometrial Cancer | 0.47 | Medium | 75% |
| Glioma | 0.43 | Medium | 60% |
| Lymphoma | 0.40 | Medium | 80% |
| Bladder Cancer | 0.39 | Medium | 73% |
| Gastric Cancer | 0.36 | Medium | 64% |
| Ovarian Cancer | 0.33 | Medium | 58% |
| Breast Cancer | 0.31 | Medium | 67% |
| Skin Cancer | 0.30 | Medium | 55% |
| Head and Neck Cancer | 0.25 | Medium | 75% |
| Colorectal Cancer | 0.25 | Medium | 50% |
| Neuroendocrine Tumors | 0.25 | Medium | 50% |
| Lung Cancer | 0.23 | Medium | 50% |
| Testicular Cancer | 0.23 | Medium | 50% |
| Cervical Cancer | 0.22 | Medium | 50% |
Is PLA2G5 internalized?
Nuclens has not yet extracted internalization evidence for PLA2G5. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
PLA2G5 clinical trials
Clinical-stage (up to phase 3, any modality). Nuclens hasn't indexed trials for PLA2G5 yet. Search ClinicalTrials.gov for PLA2G5 trials.
PLA2G5 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See PLA2G5 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
PLA2G5 gene essentiality (DepMap)
CRISPR knockout effect across 1225 cancer cell lines: -0.04 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related kidney cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · STEAP2 · ITGAV · Mesothelin (MSLN) · SSTR2 · HER2 (ERBB2)
See all radioligand therapy targets in kidney cancer.
See how PLA2G5 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.